Goodwin Advised Kymera Therapeutics in $690 Million Upsized Public Offering

Goodwin Advised Kymera Therapeutics in $690 Million Upsized Public Offering

The Goodwin Life Sciences team advised Kymera Therapeutics on the completion of its upsized underwritten public offering of 8,050,000 shares of its common stock at a public offering price of $86.00 per share, which included the full exercise by the underwriters of their option to purchase an additional 1,050,000 shares. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $692.3 million.

Kymera Therapeutics (Nasdaq: KYMR) is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years.

The Goodwin team was led by Jesse Fishman (Associate), and Bill Collins (Partner), Catherine Magazu (Partner), and Madison Clausius (Associate), Austin Lorenzo (Associate), and included Julie Tibbets (Partner), Maggie Wong (Partner), Dan Karelitz (Partner), and Krupa S. Zachariah (Associate).

If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.